CN108473564B - 改进的血清白蛋白结合剂 - Google Patents

改进的血清白蛋白结合剂 Download PDF

Info

Publication number
CN108473564B
CN108473564B CN201680079196.5A CN201680079196A CN108473564B CN 108473564 B CN108473564 B CN 108473564B CN 201680079196 A CN201680079196 A CN 201680079196A CN 108473564 B CN108473564 B CN 108473564B
Authority
CN
China
Prior art keywords
amino acid
seq
acid sequence
serum albumin
kabat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680079196.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN108473564A (zh
Inventor
玛丽-安格·比斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ablynx NV
Original Assignee
Ablynx NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx NV filed Critical Ablynx NV
Priority to CN202510665720.8A priority Critical patent/CN120535622A/zh
Priority to CN202210310096.6A priority patent/CN114605530B/zh
Publication of CN108473564A publication Critical patent/CN108473564A/zh
Application granted granted Critical
Publication of CN108473564B publication Critical patent/CN108473564B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201680079196.5A 2015-11-18 2016-11-17 改进的血清白蛋白结合剂 Active CN108473564B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202510665720.8A CN120535622A (zh) 2015-11-18 2016-11-17 改进的血清白蛋白结合剂
CN202210310096.6A CN114605530B (zh) 2015-11-18 2016-11-17 改进的血清白蛋白结合剂

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562256841P 2015-11-18 2015-11-18
US62/256,841 2015-11-18
US201662335746P 2016-05-13 2016-05-13
US62/335,746 2016-05-13
US201662349294P 2016-06-13 2016-06-13
US62/349,294 2016-06-13
PCT/EP2016/077973 WO2017085172A2 (en) 2015-11-18 2016-11-17 Improved serum albumin binders

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202510665720.8A Division CN120535622A (zh) 2015-11-18 2016-11-17 改进的血清白蛋白结合剂
CN202210310096.6A Division CN114605530B (zh) 2015-11-18 2016-11-17 改进的血清白蛋白结合剂

Publications (2)

Publication Number Publication Date
CN108473564A CN108473564A (zh) 2018-08-31
CN108473564B true CN108473564B (zh) 2022-04-08

Family

ID=57326420

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201680079196.5A Active CN108473564B (zh) 2015-11-18 2016-11-17 改进的血清白蛋白结合剂
CN202210310096.6A Active CN114605530B (zh) 2015-11-18 2016-11-17 改进的血清白蛋白结合剂
CN202510665720.8A Pending CN120535622A (zh) 2015-11-18 2016-11-17 改进的血清白蛋白结合剂

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202210310096.6A Active CN114605530B (zh) 2015-11-18 2016-11-17 改进的血清白蛋白结合剂
CN202510665720.8A Pending CN120535622A (zh) 2015-11-18 2016-11-17 改进的血清白蛋白结合剂

Country Status (7)

Country Link
US (2) US11332519B2 (enExample)
EP (1) EP3377525A2 (enExample)
JP (3) JP7046804B2 (enExample)
CN (3) CN108473564B (enExample)
AU (2) AU2016357460B2 (enExample)
CA (1) CA3005488A1 (enExample)
WO (1) WO2017085172A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6258199B2 (ja) 2011-06-23 2018-01-10 アブリンクス エン．ヴェー． 免疫グロブリン単一可変ドメインを伴うアッセイにおける非特異的タンパク質干渉を予測、検出及び低減するための技術
SI3248986T1 (sl) * 2014-05-16 2022-04-29 Ablynx Nv Variabilne domene imunoglobulina
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
JP6936797B2 (ja) 2015-10-30 2021-09-22 アブリンクス エン．ヴェー． Ｉｌ−２３に対するポリペプチド
EP3541846A1 (en) 2016-11-16 2019-09-25 Ablynx NV T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
MA48760A (fr) 2017-05-31 2020-04-08 Boehringer Ingelheim Int Polypeptides ayant un effet antagoniste sur la signalisation wnt dans des cellules tumorales
US12129308B2 (en) 2017-06-02 2024-10-29 Merck Patent Gmbh MMP13 binding immunoglobulins
CN111138536B (zh) * 2018-11-06 2021-07-09 瑞阳(苏州)生物科技有限公司 抗人血清白蛋白单域抗体的制备及其应用
CN111138537B (zh) * 2018-11-06 2021-07-09 瑞阳(苏州)生物科技有限公司 一种抗人血清白蛋白抗体片段、制备方法和应用
CN112409480B (zh) * 2019-08-20 2024-08-27 四川科伦博泰生物医药股份有限公司 结合血清白蛋白的蛋白及其用途
AU2020397210A1 (en) * 2019-12-06 2022-07-28 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting TNFa and OX40L
CA3163877A1 (en) 2019-12-06 2021-06-10 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting tnf.alpha. and il-23
TW202530257A (zh) 2019-12-09 2025-08-01 比利時商艾伯霖克斯公司 包含靶向il-13及tslp之免疫球蛋白單可變域的多肽
CN115916818A (zh) * 2019-12-11 2023-04-04 库利南肿瘤股份有限公司 抗cd19抗体和多特异性结合蛋白
CN110988361B (zh) * 2019-12-13 2020-09-18 山东民康生物科技有限公司 人血清白蛋白去除试剂盒
MX2022012278A (es) 2020-03-30 2022-10-27 Ablynx Nv Metodo para la produccion y purificacion de dominios variables unicos de inmunoglobulina multivalentes.
MX2023003522A (es) 2020-09-25 2023-04-19 Ablynx Nv Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y ox40l.
US11897951B2 (en) 2020-12-18 2024-02-13 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α
IL303783A (en) 2020-12-18 2023-08-01 Sanofi Sa Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
US20240092919A1 (en) 2020-12-18 2024-03-21 Ablynx N. V. T cell recruiting polypeptides based on tcr alpha/beta reactivity
MX2024007564A (es) 2021-12-17 2024-07-04 Ablynx Nv Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tcr\03b1\03b2, cd33 y cd123.
AR129614A1 (es) 2022-06-14 2024-09-11 Ablynx Nv Dominios variables únicos de inmunoglobulina que se dirigen al receptor de células t
MA71603A (fr) 2022-07-27 2025-05-30 Ablynx Nv Polypeptides se liant à un épitope spécifique du récepteur fc néonatal
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
KR20250133750A (ko) 2023-01-09 2025-09-08 오디세이 테라퓨틱스, 인코포레이티드 항-tnfr2 항원-결합 단백질 및 그의 용도
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
AU2024234615A1 (en) 2023-03-14 2025-08-21 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
AR132699A1 (es) 2023-05-17 2025-07-23 Odyssey Therapeutics Inc Anticuerpos de dominio único modificados
WO2024261235A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Chimeric proteins for modulating cytokine receptor activity
AU2024308381A1 (en) 2023-06-29 2025-11-20 Odyssey Therapeutics, Inc. Anti-trailr2 antigen-binding proteins and uses thereof
AR133188A1 (es) 2023-07-05 2025-09-03 Ablynx Nv ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
WO2025051767A1 (en) 2023-09-04 2025-03-13 Sanofi Polypeptides for use in the treatment of glypican-3-expressing tumours
AR133903A1 (es) 2023-09-22 2025-11-12 Ablynx Nv Agentes de unión de albúmina bi- y multivalentes
TW202530265A (zh) 2023-10-13 2025-08-01 美商奧迪希治療公司 抗cdh17抗原結合蛋白及其用途
WO2025099632A1 (en) 2023-11-08 2025-05-15 Sanofi Cd25 based lysosomal degrader and uses thereof
WO2025106915A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof
WO2025114529A1 (en) 2023-12-01 2025-06-05 Ablynx Nv Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety
WO2025133166A1 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based carriers for site-specific amine conjugation
WO2025133253A2 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based conjugation carriers for intranuclear delivery
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
US12459994B2 (en) 2024-04-12 2025-11-04 Paragon Therapeutics, Inc. Albumin binding proteins and methods of use
WO2025255558A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
WO2025255435A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Antigen-binding proteins against serum albumin and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101248087A (zh) * 2005-05-18 2008-08-20 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
CN103619878A (zh) * 2011-06-23 2014-03-05 埃博灵克斯股份有限公司 结合血清白蛋白的蛋白
WO2014087010A1 (en) * 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
CN103917557A (zh) * 2011-08-17 2014-07-09 葛兰素集团有限公司 具有降低的与抗药物抗体结合的经修饰的单可变结构域抗体
CN104203975A (zh) * 2011-06-23 2014-12-10 埃博灵克斯股份有限公司 用于预测、检测和减少涉及免疫球蛋白单可变结构域的测定法中的非特异性蛋白干扰的技术
CN106661100A (zh) * 2014-05-16 2017-05-10 埃博灵克斯股份有限公司 改进的免疫球蛋白可变结构域

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
EP1027439B1 (en) 1997-10-27 2010-03-17 Bac Ip B.V. Multivalent antigen-binding proteins
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
NZ540196A (en) 2002-11-08 2008-09-26 Ablynx Nv Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
US9028816B2 (en) 2003-01-10 2015-05-12 Ablynx N.V. Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor
US20090191217A1 (en) 2004-12-02 2009-07-30 De Wildt Ruud M Anti-IL-1R1 Single Domain Antibodies And Therapeutic Uses
ES2694247T3 (es) 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
CA2629850A1 (en) 2005-12-01 2007-06-07 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
JP2009519011A (ja) 2005-12-01 2009-05-14 ドマンティス リミテッド インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
EP1976991A1 (en) 2006-01-24 2008-10-08 Domantis Limited Fusion proteins that contain natural junctions
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
WO2009138519A1 (en) 2008-05-16 2009-11-19 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
CN101796072B (zh) 2007-05-24 2014-09-24 埃博灵克斯股份有限公司 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
EP2215125A1 (en) 2007-11-27 2010-08-11 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
EP2403873A1 (en) 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
EA201270174A1 (ru) 2009-07-16 2012-07-30 Глэксо Груп Лимитед Отдельные связывающиеся вариабельные домены с улучшенными свойствами, направленные против сывороточного альбумина
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
CN107646039B (zh) * 2015-04-02 2022-04-15 埃博灵克斯股份有限公司 具有有效抗hiv活性的双特异性cxcr4-cd4多肽
WO2017081211A2 (en) * 2015-11-10 2017-05-18 University Medical Center Hamburg - Eppendorf Antigen-binding polypeptides directed against cd38
CA3004900C (en) * 2015-11-18 2021-08-10 Merck Sharp & Dohme Corp. Ctla4 binders
CA3003777A1 (en) * 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Pd1/ctla4 binders
MA43260A (fr) * 2015-11-18 2018-09-26 Merck Sharp & Dohme Liants pd1 et/ou lag3

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101248087A (zh) * 2005-05-18 2008-08-20 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
CN103619878A (zh) * 2011-06-23 2014-03-05 埃博灵克斯股份有限公司 结合血清白蛋白的蛋白
CN104203975A (zh) * 2011-06-23 2014-12-10 埃博灵克斯股份有限公司 用于预测、检测和减少涉及免疫球蛋白单可变结构域的测定法中的非特异性蛋白干扰的技术
CN103917557A (zh) * 2011-08-17 2014-07-09 葛兰素集团有限公司 具有降低的与抗药物抗体结合的经修饰的单可变结构域抗体
WO2014087010A1 (en) * 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
CN106661100A (zh) * 2014-05-16 2017-05-10 埃博灵克斯股份有限公司 改进的免疫球蛋白可变结构域

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
血清白蛋白序列中的相似氨基酸突变特点分析;陆会宁,齐燕姣,冯树华,李世玺,赵娅敏,金能智;《生物信息学》;20150915;第13卷(第3期);179-185 *

Also Published As

Publication number Publication date
US20220380445A1 (en) 2022-12-01
JP2022037133A (ja) 2022-03-08
CN114605530B (zh) 2025-06-10
JP7046804B2 (ja) 2022-04-04
US11332519B2 (en) 2022-05-17
CA3005488A1 (en) 2017-05-26
CN108473564A (zh) 2018-08-31
AU2016357460B2 (en) 2023-07-27
WO2017085172A3 (en) 2017-06-29
AU2016357460A1 (en) 2018-05-17
EP3377525A2 (en) 2018-09-26
US20200283509A1 (en) 2020-09-10
JP2024063213A (ja) 2024-05-10
CN114605530A (zh) 2022-06-10
CN120535622A (zh) 2025-08-26
JP7453206B2 (ja) 2024-03-19
WO2017085172A2 (en) 2017-05-26
JP2019503990A (ja) 2019-02-14
AU2023229506A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
CN108473564B (zh) 改进的血清白蛋白结合剂
US20220112275A1 (en) Serum albumin-binding immunoglobulin variable domains
EP3571225B1 (en) Improved serum albumin binders
EP3571224B1 (en) Improved serum albumin binders
CA3005061C (en) Improved serum albumin-binding immunoglobulin variable domains
HK40118030A (en) Improved serum albumin binders
HK40117444A (en) Improved serum albumin binders
HK40017968B (en) Improved serum albumin binders
HK40017968A (en) Improved serum albumin binders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant